Medvolt

Medvolt's Pipeline

DIVERSIFIED PIPELINE
DISCOVERED USING MedGraphTM

Medvolt.ai

Reach out to us at contact@medvolt.ai for partnering opportunities

  • Indication
    Target
    Type
    Stage
  • Pan-Oncology (Breast, Prostate, Ovarian Cancer)
    Undisclosed*
    NCE
    Pre-DiscoveryDiscoveryPre-Clinical / IND-enablingClinical
  • Triple Negative Breast Cancer (TNBC)
    Undisclosed*
    RPE
    Pre-DiscoveryDiscoveryPre-Clinical / IND-enablingClinical
  • Inflammatory Disorders
    Undisclosed*
    NCE
    Pre-DiscoveryDiscoveryPre-Clinical / IND-enablingClinical
  • Peptic Ulcer
    Undisclosed*
    RPE
    Pre-DiscoveryDiscoveryPre-Clinical / IND-enablingClinical

NCE :

New Chemical Entity

RPE :

Re-purposed Entity

Undisclosed* :

Programs across targets have advanced in various stages. More information on targets will be provided upon CDA

Why Medvolt

Accelerate Discovery

Medvolt's AI-powered platform cuts pre-clinical discovery time by 3x, reduces costs by 15x and lowers failure risk by 25%. Enhance your R&D efficiency with our in silico tools.

High-Throughput Data

Enrich your research with Medvolt's proprietary, gold-standard, high-throughput proprietary datasets. Our AI and NLP solutions deliver speed, precision and scalability.

Expert Collaboration

Our experienced, tech-driven team collaborates globally with leading pharma and biotech companies, ensuring impactful, scalable solutions.